RxDoctor Payments Data

Lisa Conniff

Physician Assistant · Parsons, WVNPI 1528097524

Payments from drug & device makers

$644in general payments, 2019–2025

Across 30 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$233
  • Novo Nordisk$161
  • AstraZeneca$113
  • AbbVie$55
  • Mylan Specialty L.p.$27
  • Xeris Pharmaceuticals, Inc.$25
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$644100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$644 in reported general payments places this provider in the 65th percentile of 833 physician assistant providers in West Virginia.

See all physician assistant providers in West Virginia

Medicare billing

Part B allowed, 2024
$2,422
Medicare patients
66
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate57$71,443
Tresiba Flextouch U-200Insulin Degludec44$61,574
JardianceEmpagliflozin43$47,875
TrulicityDulaglutide32$36,620
EliquisApixaban46$35,584
OzempicSemaglutide33$32,769
MounjaroTirzepatide19$30,322
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$12,281
Breo ElliptaFluticasone/Vilanterol19$10,369
LinzessLinaclotide12$6,105
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$5,227
VascepaIcosapent Ethyl12$4,107
SymbicortBudesonide/Formoterol Fumarate15$4,091
ErythromycinErythromycin Base12$2,166
Metoprolol Succinate118$1,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$35,58446 claims
Novo NordiskOzempic$161$32,76933 claims
AbbVieLinzess$55$6,10512 claims
AstraZenecaSymbicort$113$4,09115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 833 physician assistant providers in West Virginia.

Other physician assistant in Parsons

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →